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abstract
Only approximately 1.5% of the human genome encodes protein 
sequence; the rest is ‘dark matter’. Research on these noncoding 
regions shows that they play roles in cellular homeostasis, 
development, differentiation and metabolism. Cancer, 
cardiovascular, developmental, and neurological diseases are 
characterised by aberrant expression of these regions. Exploring 
their clinical utility as biomarkers and molecular targets in 
medical theranostics is a very promising way forward.
IntroductIon
It is now well known that only approximately 1.5% of the human 
genome encodes protein sequence.1 However, comparative 
analyses with mammalian genomes have shown that at least 
5% is under selective constraint and thus probably functional, 
of which approximately 3.5% consists of noncoding elements 
with apparent regulatory roles.2 Collectively, this created 
an aura of mystery, leading to the label of ‘dark matter’, in 
a manner analogous to the ‘dark matter’ of the universe, 
which we can neither easily detect nor understand, but that 
nonetheless exists and is open to experimental queries. Ongoing 
research on these noncoding regions, which form a major 
part of this once proverbial genomic ‘dark matter’, shows 
that they play vital biological roles in cellular homeostasis, 
development, differentiation and metabolism. Indeed, their 
aberrant expression is being found in a variety of human 
diseases, including cancer, cardiovascular, developmental, and 
neurological diseases. Consequently, translational research is 
exploring the clinical utility of these noncoding RNAs (ncRNAs) 
as biomarkers and molecular targets in medical theranostics.
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ncRNAs represent a significant portion of the human 
transcriptome. Based on their size, ncRNAs are grouped into 
two major classes, namely, small ncRNA and long ncRNA 
(lncRNA). microRNAs (miRNAs, approximately 22 nucleotides 
long) and transcription initiation RNAs (tiRNAs, 18 nucleotides 
long) are two examples of the first class. In contrast, lncRNAs, 
which resemble mRNA transcripts, range from 200 nucleotides 
to approximately 100 kilobases.3 In humans, lncRNAs have been 
identified to be transcribed from four chromosomal regions, 
termed the Hox gene loci. These four Hox loci (Hoxa, Hoxb, 
Hoxc and Hoxd) include dozens of genes that are involved 
in a variety of biological processes, including embryonic 
development, cell differentiation and tumorigenesis.4
Several lncRNAs are coded from regions between the 
genes in these Hox clusters, hence their other name being long 
intergenic non-coding RNA, or lincRNA. Increasing numbers of 
lncRNAs are being identified and their functions investigated. In 
fact, an emerging function is their role in genome modification, 
where they associate with Polycomb proteins to epigenetically 
silence genes. Specifically, this can occur through histone tail 
post-translational modifications, with methylation of histone H3 
lysine 9 (H3K9me), lysine 27 (H3K27me), and histone H4 lysine 
20 (H4K20me) being associated with regions of the genome that 
are transcriptionally inactive. Such silencing of genes through 
histone methylation is thought to be mediated by chromatin 
modelling complexes such as the Polycomb repressive complexes 
(PRC), PRC1 and PRC2. In this review, we will focus on what 
are perhaps the three most valued Polycomb-related lncRNAs in 
the clinical setting, i.e. ANRIL, HOTAIR, and XIST.
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1. anrIl
Spanning 126.3 kilobases in the genome, ANRIL is an antisense 
ncRNA in the INK4 locus. The INK4b (p15)–ARF (p14)–INK4a 
(p16) locus, which is found on chromosome 9p21, is said to be 
an essential regulator of cellular senescence. INK4 carries out 
this regulatory role by coding for three tumour suppressors i.e. 
p14 which increases p53 signalling, and  p15 and p16, which (a) 
promote the function of the retinoblastoma protein pRB, and 
also, (b) inhibit cyclin-dependent kinases therefore causing cell 
cycle arrest. Regulation of the INK4 locus is governed by the 
Polycomb repressive complexes PRC1 and PRC2, where PRC2 
initially trimethylates H3K27 in the transcriptionally silent 
heterochromatin, and then PCR1 recognises the methylated 
H3K27 as a sign to maintain the heterochromatin. Both cis- and 
trans-acting lncRNAs recruit Polycomb complexes to establish 
the heterochromatin. In this case, PRC1 and PRC2 are recruited 
to the INK4 locus by the lncRNA ANRIL, which is expressed 
antisense to the p14 and the p15 tumour suppressors.
It has been suggested that both Polycomb repressive 
complexes are recruited in cis to the INK4 locus gene through 
association with nascent ANRIL transcripts. Such a suggestion 
was made following results from a study showing that 
ANRIL knockdown leads to the upregulation of p15 and p16. 
Furthermore, the transcriptional state of the locus, which is 
often deleted or silenced in cancer, appears to be affected by 
changes in ANRIL expression.5 Upregulation of ANRIL is seen 
in prostate cancer tissues for instance,6 and in heart disease, type 
2 diabetes, and risk-associated single-nucleotide polymorphisms 
(SNPs) for cancers overlapping with the ANRIL region.7 One 
SNP in the 9p21 gene desert was also shown to be associated 
with coronary artery disease; this DNA variant disrupts the 
binding site for the STAT1 transcription factor which is known 
to represses the expression of ANRIL. Therefore, by stopping 
STAT1 from binding, it leads to the upregulation of ANRIL, 
and the cause behind coronary artery disease might well be the 
ANRIL-mediated silencing of p15.8 Similar to ANRIL is the 
lncRNA HEIH which was also found to regulate the INK4 locus, 
where by recruiting PRC2 to tumour suppressors, it facilitates 
hepatocellular carcinoma tumorigenesis.9
2. hotaIr
HOTAIR is one of the recently identified lncRNAs. It is a 
2,158-nucleotide-long, spliced and polyadenylated lncRNA, 
encoded by a 6,232 base pair gene, located in the Hoxc cluster 
on chromosome 12 (specifically at 12q13). Only one strand 
of HOTAIR, which is antisense to the canonical Hoxc genes, 
is transcribed; hence its name, standing for Hox Antisense 
Intergenic RNA.10 Unlike other documented lncRNAs that 
act strictly in cis (such as XIST), HOTAIR is the first lncRNA 
that is said to function in trans, because it is transcribed by 
one chromosome (chromosome 12), but regulates chromatin 
domains on another chromosome.11 HOTAIR exists only in 
mammals, has been highly conserved in primates throughout 
evolution, and has evolved faster than nearby HoxC genes. 
Poorly conserved sequences are present in its six exons, except 
for a 239 base pair domain in exon 6, which is particularly 
conserved.12
Presently, the proposed functional mechanism of HOTAIR 
is to act as a scaffold for the recruitment and binding of the 
polycomb complex PRC2 and lysine-specific demethylase 1 
(LSD1). PRC2 and LSD1 are multisubunit protein complexes 
that epigenetically modify chromatin. HOTAIR is believed 
to recruit these two complexes to regions of the genome so 
as to bring about gene silencing. For this reason, HOTAIR is 
emerging as an important player in tumorigenesis. It was found 
that high levels of HOTAIR are linked with metastatic spread 
and poor survival rate in breast cancer.13 Specifically, HOTAIR 
was shown to be highly upregulated in primary and metastatic 
breast tumours, even up to two-thousandfold over normal breast 
tissue. HOTAIR expression levels were also found to correlate 
with metastasis in colorectal cancer,14 gastrointestinal stromal 
tumours,15 hepatocellular carcinoma,16-17 and pancreatic cancer.18
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3. XIst
XIST, or X inactive specific transcript, is a mammalian lncRNA 
located in the X chromosome inactivation centre. Its gene 
product is first transcribed from the inactive X chromosome, 
and then, it spreads along the same X chromosome from which 
it was transcribed. In mammals, silencing of one of the two X 
chromosomes is necessary to achieve dosage compensation. The 
lncRNA XIST triggers X chromosome inactivation (XCI) in cells 
of the early embryo and in hematopoietic progenitors where 
silencing factors are present. XIST is not however required for 
the maintenance of XCI. XIST is also found to be expressed in 
adult females, and for this reason, it is suggested that the loss of 
XIST in adults could lead to the reactivation of inactive X genes. 
Having said this, the exact molecular mechanism by which XIST 
inactivates the X chromosomes remains unclear.
Nonetheless, surmounting evidence suggests that XIST 
has a role in the differentiation and proliferation of human 
cells. In fact, the dysregulated expression of XIST may play a 
pathologic role in cancer, which could be related to changes 
in gene expression, from the alterations to the stability of 
heterochromatin. It is possible that cancer cells produce 
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silencing factors that allow for the inactivation of the X 
chromosome outside of the context of embryonic development. 
SATB1 (or special AT-rich sequence-binding protein-1), for 
instance, has been identified as a factor related to XIST-mediated 
chromosome silencing, and its aberrant expression was shown 
to promote breast, hepatocellular, prostate and other types of 
cancer.19 XIST silencing has also been reported in transgenic male 
fibrosarcoma cell lines, again suggesting a special context whereby 
X chromosome inactivation through XIST can occur in cancer 
cells.20
conclusIon
ANRIL, HOTAIR and XIST are merely three of the ncRNAs that 
are currently being investigated. To mention but a few, others 
include Dleu2, EGO, lncRNA-a7, lncRNA-P21, and MEG3, each 
with an equal potential for being the missing piece of the puzzle. 
It is not therefore impossible to envisage a therapeutic world 
based on ncRNAs. Presently, however, the main challenge in 
introducing ncRNA-based therapeutics into clinical practice is the 
delivery and the off-target effects. Breakthroughs in both of these 
areas will pave the way forward for the future of medicine. 
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